Smartleaf Asset Management LLC Has $2.84 Million Stock Holdings in Stryker Corporation $SYK

Smartleaf Asset Management LLC increased its position in shares of Stryker Corporation (NYSE:SYK) by 36.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,679 shares of the medical technology company’s stock after purchasing an additional 2,068 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Stryker were worth $2,840,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Canada Post Corp Registered Pension Plan increased its holdings in shares of Stryker by 3.5% during the third quarter. Canada Post Corp Registered Pension Plan now owns 13,960 shares of the medical technology company’s stock worth $5,164,000 after buying an additional 471 shares in the last quarter. Appleton Partners Inc. MA grew its position in Stryker by 2.5% during the 3rd quarter. Appleton Partners Inc. MA now owns 30,254 shares of the medical technology company’s stock worth $11,184,000 after acquiring an additional 745 shares during the last quarter. Concord Wealth Partners increased its holdings in Stryker by 7.1% during the 3rd quarter. Concord Wealth Partners now owns 1,035 shares of the medical technology company’s stock valued at $383,000 after purchasing an additional 69 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in Stryker by 7.7% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 20,494 shares of the medical technology company’s stock valued at $7,576,000 after purchasing an additional 1,460 shares during the last quarter. Finally, Black Diamond Financial LLC boosted its stake in Stryker by 12.8% in the third quarter. Black Diamond Financial LLC now owns 1,968 shares of the medical technology company’s stock worth $728,000 after purchasing an additional 224 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CAO William E. Berry, Jr. sold 1,953 shares of Stryker stock in a transaction on Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the transaction, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at $1,035,433.17. This trade represents a 40.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Preston Wendell Wells sold 165 shares of the business’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total transaction of $60,370.20. Following the completion of the transaction, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at $2,449,200.72. This trade represents a 2.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 252,118 shares of company stock worth $91,504,172. Company insiders own 5.20% of the company’s stock.

Stryker Trading Down 1.1%

NYSE SYK opened at $358.49 on Monday. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $404.87. The stock has a 50-day simple moving average of $358.39 and a 200 day simple moving average of $370.46. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $137.09 billion, a PE ratio of 42.68, a P/E/G ratio of 2.10 and a beta of 0.87.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.40 by $0.07. The company had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the previous year, the company earned $4.01 EPS. Research analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s dividend payout ratio is presently 41.90%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on SYK. UBS Group set a $408.00 target price on Stryker in a research note on Monday, October 13th. Citigroup restated a “market outperform” rating on shares of Stryker in a research report on Friday, January 30th. TD Cowen downgraded shares of Stryker from a “buy” rating to a “hold” rating and set a $387.00 target price for the company. in a research note on Monday, January 26th. Sanford C. Bernstein increased their price target on shares of Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Finally, Citizens Jmp upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 price objective for the company in a research report on Friday, December 19th. Twelve equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average price target of $426.94.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.